Drägerwerk stock reports 7.7 percent sales growth in H1 2026

Published on 10/06/2026 at 15:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Drägerwerk stock was trading at EUR 115.60 on October 6, 2026, with a market value of EUR 2.2 billion. Management guides for a 6 percent to 8 percent EBIT margin, with third-quarter results due October 29.

Architekturvisualisierung eines modernen Medizintechnik-Forschungsgebäudes mit Glasfassade — Drägerwerk AG & Co. KGaA modernes Forschungsgebäude Medizintechnik Glasfassade Architekturrender Unternehmensanlage DE0005550636, Illustration mit AI erstellt.

Drägerwerk stock (ISIN DE0005550636) was trading at EUR 115.60 on Xetra on October 6, 2026 at 2:37 p.m. CEST, up 0.87 percent from the prior close of EUR 114.60. The company reported 7.7 percent currency-adjusted sales growth in the first half of 2026, making operating profitability the central issue for the shares.

Sales growth supports the margin story

According to Yahoo Finance on July 30, 2026, first-half net sales increased 7.7 percent, while EBIT rose from EUR 20 million to EUR 64 million. The EBIT margin therefore reached 4.0 percent, compared with 1.3 percent in the prior-year period.

The improvement was supported by both operating performance and customs refunds. The reported figures combine stronger sales with a wider margin, but the one-off refunds make the quality of the earnings improvement an important point for the next report.

Guidance sets the next benchmark

Yahoo Finance reported that management expects currency-adjusted sales growth of 2 percent to 6 percent for 2026 and an EBIT margin of 6 percent to 8 percent. The current margin range is above the 4.0 percent reported for the first half, so execution in the second half will determine whether the guidance is achieved.

Drägerwerk also plans to discuss its longer-term strategy at a capital markets day on November 18, 2026, according to the same July 30 earnings-call transcript. The company says its medium-term ambition is to raise the EBIT margin to 10 percent by 2030, a target that gives the current margin progress a longer horizon.

Analyst target stays above the price

According to Finanztrends on September 8, 2026, MWB Research raised its Drägerwerk price target from EUR 114 to EUR 130. At the October 6 price of EUR 115.60, the new target lies 12.5 percent above the stock price.

The market value stood at EUR 2.2 billion on October 6, 2026. The 52-week range was EUR 64.50 to EUR 125.40, placing the stock 7.7 percent below its yearly high and keeping the margin outlook more important than a simple valuation comparison.

Drägerwerk stock stays below its yearly high

Drägerwerk stock was last at EUR 115.60 on Xetra on October 6, 2026 at 2:37 p.m. CEST, with 5,534 shares traded in the quoted session. The next scheduled company checkpoint is the third-quarter results release on October 29, 2026, as reported by Finanztrends.